Jim Dillon has been named CEO of BiVACOR. Photo courtesy of BiVACOR

Houston-based medical device company BiVACOR has brought aboard a new CEO.

Jim Dillon, a longtime executive in the medical device sector, has been hired to lead BiVACOR and join its board of directors. Dillon succeeds former heart surgeon Dr. Thomas Vassiliades, whose appointment as CEO was announced in January 2022.

“Jim’s leadership style, combined with his experience in building high-performance teams as well as expertise in the heart failure field, makes him the ideal person to lead BiVACOR,” Raymond Cohen, chairman of BiVACOR, says in a news release.

Cohen was named chairman of BiVACOR in December 2023.

Most recently, Dillon was CEO of Massachusetts-based BioVentrix, a medical device company that focuses on minimally invasive procedures aimed at preventing heart failure. He previously held sales and marketing positions at medical device companies Abiomed, TherOx, and InfraReDx.

In November, the U.S. Food and Drug Administration (USDA) paved the way for BiVACOR to conduct a first-in-human clinical feasibility study of its Total Artificial Heart product. The study, initially featuring three patients at Houston’s Texas Heart Institute, is set to start during the first half of 2024. It will evaluate the device’s use as a substitute for a heart transplant.

The device “is unique in its complexity and importance as an advanced treatment option for end-stage biventricular heart failure patients,” Dillon says, and promises “to truly revolutionize the field.”

About 100,000 patients suffering from severe heart failure could benefit from BiVACOR’s artificial heart, the company says. For these patients, drug therapy is limited and the health prognosis is bleak, given the scarcity of donor hearts around the world.

Founded in 2008, BiVACOR maintains its headquarters in Houston, along with offices in Huntington Beach, California, and Brisbane, Australia.

To date, BiVACOR has raised nearly $37.8 million, according to CB Insights. The company’s investors include Boston-based Cormorant Asset Management, Australia-based OneVentures, the Australia Department of Health, and the National Institutes of Health (NIH).

SeisWave specializes in cost-effective, cloud-based seismic data processing. Photo via Getty Images

Houston energy startup joins Texas-based climate accelerator

ready to grow

An Austin-based climate accelerator announced its 2023 cohort, which includes a Houston cleantech startup.

StudioX named seven startups to its 2023 cohort, and SeisWave Corp., a seismic service company, will join the program that aims to help the world reach net-zero targets by 2050. The group comprises Studio X's third cohort since the company launched in 2020.

SeisWave specializes in cost-effective, cloud-based seismic data processing.

Other companies in the cohort include:

  • AI Technology & Systems: A NASA iTech company that provides compressed AI models and software
  • Austere Environmental: An environmental remediation solution that extracts chemical contaminants in soil, drill cuttings, and tailings
  • Economical Energy: A long-duration energy storage solution company
  • Flexergy: A developing highly efficient hydrogen gas compression, storage and distribution system
  • Onvol: An IoT power solutions tech company with applications in wind energy, transport, and mining
  • Project Geminae: A Midland, Texas-based AI-powered portfolio optimization platform advancing predictive modeling across industries

The companies will participate in a 16-week program and mentorship through the cohort, along with investment opportunities.

“Our accelerator program helps to close that gap through bringing together an engaged community that grows these companies at a faster rate, ultimately driving innovation, and helping to evolve global energy solutions,” Jeff Allyn, CEO of Studio X, says in a statement.

Studio X is fully-owned and incubated by Shell and aims to "break down the silos of traditional R&D," according to its website. Click here to view some of the accelerator's past participants.

The company will host an Accelerator Showcase Event Friday, Nov. 10, where companies will pitch their concepts and offer a Q&A session. Register here.

Another Shell-backed accelerator announced its cohort earlier this week. In partnership with Greentown Labs, the organizations announced the cohort for Greentown Go Make 2023, which aims to accelerate partnerships between startups and corporations to advance carbon utilization, storage, and traceability solutions. The cohort includes six companies from around the world, from the Netherlands and Canada to Massachusetts and Washington state.

Additionally, The Goodwill Clean Tech Accelerator will launch in Houston next year to help advance clean tech jobs. According to Accenture and Goodwill, which are partners in the accelerator, said it plans to grow the program to 20 cities in the next seven years and train an estimated 7,000 job seekers.

———

This article originally ran on EnergyCapital.

Meet Michelle Accardi, the new CEO of Liongard. Photo courtesy of Liongard

Houston SaaS startup names new CEO

c-suite switchup

A Houston startup founder is transitioning from CEO to make room for a new leader.

Liongard, a software-as-a-service startup with a Managed Service Providers platform, has named Michelle Accardi as CEO, effective April 17. Joe Alapat, co-founder and CEO, will transition to CTO to better lead tech development of the platform, which provides customers with compliance, cybersecurity risk mitigation, and more.

“Now is the right time for Liongard to transform for the long term as we welcome a new member to our executive leadership team,” Alapat says in a news release. “Michelle’s addition will help take Liongard to the next level and accelerate our growth as we address the evolving needs of the industry. This new role allows me to focus on driving Liongard’s innovation forward and helping our MSP partners navigate the modern business landscape.”

Accardi has over 20 years of experience within MSPs and technology companies. She will oversee growth of the company and its product portfolio.

“The Liongard team has accomplished much in its first few years, and that’s a testament to the founding vision and hard work of the entire organization,” Accardi said. “With Liongard in a strong market leadership position, there is a unique opportunity to accelerate growth. Joe and team have built a dynamic company culture and robust technical foundation and I am looking forward to partnering with him to build on the company’s success.”

Most recently as CEO of Logically, Accardi also served as president and chief revenue officer of Star2Star.

“We are excited to welcome Michelle to the team at Liongard,” says Carter Griffin, Liongard board member and general partner at Updata Partners, an investor of Liongard. “We believe that Michelle’s leadership experience and excellent track record will ensure Liongard continues to perform at a very high level.”

Accardi joins the team following a $10 million round of funding that Liongard, which was founded in 2015, secured last year. The startup has raised over $30 million in investment funding to date.

Joe Alapat has transitioned to CTO of Houston-based Liongard. Photo courtesy of Liongard

Houston-based Saranas has tapped a new leader amidst push to commercialize bleed detection technology. Photo via LinkedIn

Houston medical device startup names new CEO

now at the helm

Houston-based medical device company Saranas has tapped a veteran of the healthcare industry as its new CEO.

Mike MacKinnon most recently was president and partner at Madison Ventures +, a private equity firm based in Greenwood Village, Colorado. The firm invests in companies in healthcare, real estate, finance, and other sectors.

Before joining Madison Ventures +, MacKinnon was CEO of Zidan Medical, a startup focused on treatment of airway lesions in patients with early stage lung cancer. He served in that role from 2019 to 2023.

Earlier, he was CEO of ROX Medical, a medical device company specializing in minimally invasive vascular therapy for patients with uncontrolled high blood pressure. He held that role from 2018 to 2019. He previously worked at Philips North America, Volcano, AtheroMed, Hansen Medical, Access Closure, and FoxHollow Technologies.

In a news release, Dan Wolterman, chairman of Saranas’ board and former president and CEO of Memorial Hermann Health System, calls MacKinnon “an accomplished executive with an impressive record of bringing disruptive technology to market, guiding strategy, and driving significant growth.”

Now president and CEO of Nashua, New Hampshire-based medical device company Conformal Medical, James Reinstein was president and CEO of Saranas from 2020 to 2022. Prior to Reinstein, Zaffer Syed held that position from 2017 to 2020. He's still an adviser for the company and recently announced his role as entrepreneur in residence at the Texas Medical Center.

Saranas is working on commercializing its Early Bird Bleed Monitoring System, touted as the first and only system FDA-approved bleeding detection system for procedures involving blood vessels. It is designed to detect bleeds early, enabling physicians to reduce medical risks and potentially avoid costly medical problems.

“Bleeding remains a common issue during and after endovascular procedures and can result in life-threatening complications,” says MacKinnon.

Since being founded in 2013, Saranas has treated over 1,200 patients with its device and has received $29.2 million in funding, according to Crunchbase. This includes a $12.8 million Series B round that Saranas got in 2021 from Chicago-based Baird Capital and Austin-based S3 Ventures.

The Early Bird device was developed at Houston’s Texas Heart Institute. The FDA approved the device in 2019.

Here's what factors a VC will consider when evaluating a startup's leadership, according to Rice University research. Photo via Getty images

Houston research: Why venture capital firms might change a startup's leadership

houston voices

Consider the 21st century's most storied CEOs: Steve Jobs, Bill Gates, Jeff Bezos. All have one thing in common – not only did they run their companies, they founded them.

Each of these corporate leaders, in other words, had to deal with venture capital firms to find critical resources for their firm's success. And it didn't always end well. Jobs was famously fired when Apple's board replaced him with the former CEO of a soft drink company – a disaster from which Apple took years to recover.

Even if changing CEOs doesn't always work out, however, it often does. And when VCs invest heavily in a company, they are proactive in making their investment pay off. Uber founder Travis Kalanick, for example, who cofounded the ride-sharing app Uber, was pressured to step down in 2017 after the company was rocked by scandals that included reported sexual harassment.

Though Kalanick's flameout drew global attention, being swapped out is actually commonplace for CEOs of startups, according to Rice Business Professor Yan "Anthea" Zhang. In a new study coauthored with Salim Chahine of the American University of Beirut, Zhang examined data on 1,156 venture-capital-backed U.S. initial public offerings between 1995 and 2013. Out of this sample, they found that 472 firms, or 40.8 percent, changed CEOs between the first round of venture capital financing and the IPO.

Venture capitalists often have strong reasons for swapping a CEO out, Zhang notes. Guiding a company from its startup phase to the initial public offering requires a huge learning curve. Attention must be paid to human resources, efficiency, public relations – hurdles that can stymie even the most successful startup leaders. Just as in public companies, CEO deficiencies in these areas can harm a company's IPO success and its stock value after the IPO.

A range of other factors, some subtle, lie behind VC decisions to change startup leadership, the researchers found. Distance between the startup and the venture capital firm's headquarters is one such factor. If a New York VC firm funds a company in Nevada, monitoring the day-to-day work of the startup is more difficult and costly than if the venture capital firm is based in California.

A CEO directly appointed by a venture capitalist is more likely to be seen as the venture capital firm's agent, allowing the VC firm to directly control the startup, the researchers write. Overall, VC firms unable to closely monitor the startups they funded were more likely to look for new leadership.

The CEO's past experience, described by the researchers as "human capital," is also pivotal. A CEO who has successfully led a prior IPO is much less likely to be replaced than one who hasn't been through the experience, Zhang's team found. Similarly, a CEO with finance/accounting experience, an MBA, or a graduate level degree is likely to be seen as more credible than one who lacks such experience or degree.

Chaotic as it might seem to swap horses midstream, replacing a CEO for one with more experience and education correlates to a better valuation of the public offering, the researchers found.

These findings are particularly timely now, in the era of COVID-19. As businesses turn to Zoom and other remote techniques, VCs may be questioning more than ever how well they can monitor their investments without frequent site visits and in-person meetings. Building a company has always been a heavy lift. When your funder can only measure your work through a screen, surviving as a startup CEO may be tougher than ever.

------

This article originally ran on Rice Business Wisdom and is based on research from Yan "Anthea" Zhang, the Fayez Sarofim Vanguard Professor of Management – Strategic Management at Jones Graduate School of Business at Rice University.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston engineers develop breakthrough device to advance spinal cord treatment

future of health

A team of Rice University engineers has developed an implantable probe over a hundred times smaller than the width of a hair that aims to help develop better treatments for spinal cord disease and injury.

Detailed in a recent study published in Cell Reports, the probe or sensor, known as spinalNET, is used to explore how neurons in the spinal cord process sensation and control movement, according to a statement from Rice. The research was supported by the National Institutes of Health, Rice, the California-based Salk Institute for Biological Studies, and the philanthropic Mary K. Chapman Foundation based in Oklahoma.

The soft and flexible sensor was used to record neuronal activity in freely moving mice with high resolution for multiple days. Historically, tracking this level of activity has been difficult for researchers because the spinal cord and its neurons move so much during normal activity, according to the team.

“We developed a tiny sensor, spinalNET, that records the electrical activity of spinal neurons as the subject performs normal activity without any restraint,” Yu Wu, a research scientist at Rice and lead author of the study said in a statement. “Being able to extract such knowledge is a first but important step to develop cures for millions of people suffering from spinal cord diseases.”

The team says that before now the spinal cord has been considered a "black box." But the device has already helped the team uncover new findings about the body's rhythmic motor patterns, which drive walking, breathing and chewing.

Lan Luan (from left), Yu Wu, and Chong Xie are working on the breakthrough device. Photo by Jeff Fitlow/Rice University

"Some (spinal neurons) are strongly correlated with leg movement, but surprisingly, a lot of neurons have no obvious correlation with movement,” Wu said in the statement. “This indicates that the spinal circuit controlling rhythmic movement is more complicated than we thought.”

The team said they hope to explore these findings further and aim to use the technology for additional medical purposes.

“In addition to scientific insight, we believe that as the technology evolves, it has great potential as a medical device for people with spinal cord neurological disorders and injury,” Lan Luan, an associate professor of electrical and computer engineering at Rice and a corresponding author on the study, added in the statement.

Rice researchers have developed several implantable, minimally invasive devices to address health and mental health issues.

In the spring, the university announced that the United States Department of Defense had awarded a four-year, $7.8 million grant to the Texas Heart Institute and a Rice team led by co-investigator Yaxin Wang to continue to break ground on a novel left ventricular assist device (LVAD) that could be an alternative to current devices that prevent heart transplantation.

That same month, the university shared news that Professor Jacob Robinson had published findings on minimally invasive bioelectronics for treating psychiatric conditions. The 9-millimeter device can deliver precise and programmable stimulation to the brain to help treat depression, obsessive-compulsive disorder and post-traumatic stress disorder.

Houston clean hydrogen startup to pilot tech with O&G co.

stay gold

Gold H2, a Houston-based producer of clean hydrogen, is teaming up with a major U.S.-based oil and gas company as the first step in launching a 12-month series of pilot projects.

The tentative agreement with the unnamed oil and gas company kicks off the availability of the startup’s Black 2 Gold microbial technology. The technology underpins the startup’s biotech process for converting crude oil into proprietary Gold Hydrogen.

The cleantech startup plans to sign up several oil and gas companies for the pilot program. Gold H2 says it’s been in discussions with companies in North America, Latin America, India, Eastern Europe and the Middle East.

The pilot program is aimed at demonstrating how Gold H2’s technology can transform old oil wells into hydrogen-generating assets. Gold H2, a spinout of Houston-based biotech company Cemvita, says the technology is capable of producing hydrogen that’s cheaper and cleaner than ever before.

“This business model will reshape the traditional oil and gas industry landscape by further accelerating the clean energy transition and creating new economic opportunities in areas that were previously dismissed as unviable,” Gold H2 says in a news release.

The start of the Black 2 Gold demonstrations follows the recent hiring of oil and gas industry veteran Prabhdeep Singh Sekhon as CEO.

“With the proliferation of AI, growth of data centers, and a national boom in industrial manufacturing underway, affordable … carbon-free energy is more paramount than ever,” says Rayyan Islam, co-founder and general partner at venture capital firm 8090 Industries, an investor in Gold H2. “We’re investing in Gold H2, as we know they’ll play a pivotal role in unleashing a new dawn for energy abundance in partnership with the oil industry.”

------

This article originally ran on EnergyCapital.

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes an e-commerce startup founder, an industrial biologist, and a cellular scientist.

Omair Tariq, co-founder and CEO of Cart.com

Omair Tariq of Cart.com joins the Houston Innovators Podcast to share his confidence in Houston as the right place to scale his unicorn. Photo via Cart.com

Houston-based Cart.com, which operates a multichannel commerce platform, has secured $105 million in debt refinancing from investment manager BlackRock.

The debt refinancing follows a recent $25 million series C extension round, bringing Cart.com’s series C total to $85 million. The scaleup’s valuation now stands at $1.2 billion, making it one of the few $1 billion-plus “unicorns” in the Houston area.

Cart.com was co-founded by CEO Omair Tariq in October 2020. Read more.

Nádia Skorupa Parachin, vice president of industrial biotechnology at Cemvita

Nádia Skorupa Parachin joined Cemvita as vice president of industrial biotechnology. Photo courtesy of Cemvita

Houston-based biotech company Cemvita recently tapped two executives to help commercialize its sustainable fuel made from carbon waste.

Nádia Skorupa Parachin came aboard as vice president of industrial biotechnology, and Phil Garcia was promoted to vice president of commercialization.

Parachin most recently oversaw several projects at Boston-based biotech company Ginkjo Bioworks. She previously co-founded Brazilian biotech startup Integra Bioprocessos. Read more.

Han Xiao, associate professor of chemistry at Rice University

The funds were awarded to Han Xiao, a chemist at Rice University.

A Rice University chemist has landed a $2 million grant from the National Institute of Health for his work that aims to reprogram the genetic code and explore the role certain cells play in causing diseases like cancer and neurological disorders.

The funds were awarded to Han Xiao, the Norman Hackerman-Welch Young Investigator, associate professor of chemistry, from the NIH's Maximizing Investigators’ Research Award (MIRA) program, which supports medically focused laboratories. Xiao will use the five-year grant to advance his work on noncanonical amino acids.

“This innovative approach could revolutionize how we understand and control cellular functions,” Xiao said in the statement. Read more.